Business, energy, technology, markets and global industry news from Business News Today

United States Drug Enforcement Administration

PharmaDeviceNews United States Drug Enforcement Administration
Representative image: Aptar Pharma’s FDA-funded research into next-generation propellants highlights the scientific complexity behind greener metered-dose inhalers, where aerosol performance, device design and bioequivalence testing could shape the future of respiratory drug delivery.
Pharma & Biotech

Aptar Pharma just removed a critical development barrier for complex nasal drugs. How much could change?

Aptar Pharma expands DEA-authorised controlled-substance development services. See how the move could simplify nasal and inhaled drug programmes.

Read More
Otsuka’s FDA approval of SIMTRIYO, or centanafadine, introduces a first-in-class ADHD treatment for adults and children aged six and older, although DEA scheduling, safety monitoring and payer access will shape its commercial adoption. Representative image.
Pharma & Biotech

Otsuka’s SIMTRIYO has FDA approval, but two hurdles will decide whether it can disrupt ADHD care

Otsuka’s SIMTRIYO wins FDA approval for ADHD, but DEA scheduling, boxed warnings and payer access will shape its commercial uptake.

Read More